Treatment of cutaneous T-cell lymphoma with combined immunomodulatory therapy: A 14-year experience at a single institution

Archives of Dermatology

Volumn 138, Issue 8, 2002, Pages 1054-1060

  Suchin, Karen Rebecca ^a   Cucchiara, Andrew J ^a   Gottleib, Scott L ^a   Wolfe, Jonathan T ^a   DeNardo, Barbara J ^a   Macey, William H ^a   Bromley, Patricia G ^a   Vittorio, Carmela C ^a   Rook, Alain H ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; IMMUNOSTIMULATING AGENT; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RETINOID;

ARTICLE; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOMODULATION; LABORATORY TEST; MALE; PRIORITY JOURNAL; PROGNOSIS; PUVA; RISK FACTOR; T CELL LYMPHOMA; T LYMPHOCYTE; TREATMENT OUTCOME; TREATMENT PLANNING;

ADJUVANTS, IMMUNOLOGIC; COHORT STUDIES; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LYMPHOMA, T-CELL, CUTANEOUS; MALE; NEOPLASM STAGING; OUTCOME ASSESSMENT (HEALTH CARE); PHOTOPHERESIS; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; SURVIVAL RATE;

EID: 0036348257     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Cutaneous T-cell lymphoma
2. Cutaneous T-cell lymphomas: The Sézary syndrome, mycosis fungoides and related disorders
3. Mycosis fungoides and the Sézary syndrome: Pathology, staging, and treatment
4. Mycosis fungoides and the Sézary syndrome: A review of the pathogenesis, diagnosis, and therapy
5. Erythroderma avec presence de cellules monstrueses dans la derme el le sang circulant
6. Prognostic factors in erythrodermic mycosis fungoides and the Śzary syndrome
7. Prognostic variables in mycosis fungoides
8. Clinical staging for cutaneous T-cell lymphoma
9. Population-based estimate of survival and determinants of prognosis in patients with mycosis fungoides
10. Histopathologic staging at initial diagnosis of mycosis fungoides and the Sézary syndrome: Definition of three distinctive prognostic groups
11. Prognostic clinicopathologic factors in cutaneous T-cell lymphoma
12. Clinical stage IA (limited patch and plaque) mycosis fungoides: A long-term outcome analysis
13. Sézary syndrome T-cell clones display T-helper 2 cytokines and express the accessory factor-1 (interferon gamma receptor beta-chain)
14. Aberrant cytokine production by Sézary syndrome patients: Cytokine secretion pattern resembles murine Th2 cells
15. The immune response to class I-associated tumor-specific cutaneous T-cell lymphoma antigens
16. Apoptosis induction by ultraviolet light A and photochemotherapy in cutaneous T-cell lymphoma: Relevance to mechanism of action
17. Extracorporeal photochemotherapy induces the production of tumor necrosis factor-alpha by monocytes: Implication for the treatment of cutaneous T-cell lymphoma and systemic sclerosis
18. Treatment with 8-MOP and UVA enhances MHC class I synthesis in RMA cells: Preliminary results
19. Extracorporeal photochemotherapy induces a significant increase in CD36+ circulating monocytes in patients with mycosis fungoides
20. Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alpha: A 10-year experience at a single institution
21. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy: Preliminary results
22. Photopheresis therapy for cutaneous T-cell lymphoma
23. Extracorporeal photopheresis: Principles and practice
24. Report on the Committee on Staging and Classification of cutaneous T-cell lymphomas
25. Extracorporeal photochemotherapy for cutaneous T-cell lymphoma: A 9.7 year experience
26. Long-term follow-up of patients with cutaneous T-cell lymphoma treated with extracorporeal photochemotherapy
27. Extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma: The Dusseldorf and Munich experience
28. Molecular aspects of extracorporeal photochemotherapy
29. Inhibition of antiskin allograft immunity by infusions with syngeneic photoinactivated effector lymphocytes
30. Interferon alpha-2a in the treatment of cutaneous T-cell lymphoma
31. Interferon in the treatment of cutaneous T-cell lymphoma
32. IL-12 reverses cytokine and immune abnormalities in Sézary syndrome
33. Retinoids synergize with interleukin-2 to augment IFN-γ and interleukin 12 production by human peripheral blood mononuclear cells
34. Photopheresis: Clinical applications and mechanism of action